ARUP's Laboratory Test Directory

inv(16) for AML(CBFB-MYH11) by RT-PCR : 0092209

Mnemonic: INV(16)

Methodology: Reverse Transcription Polymerase Chain Reaction
Performed: Varies
Reported: 4-7 days
Specimen Required: Collect:  One 5 mL lavender (EDTA) or pink (K2EDTA), or 3 mL bone marrow (EDTA).

Transport:  3 mL whole blood (EDTA) or bone marrow (EDTA) at 2-8°C.  (Min: 1 mL)

Remarks:  Samples must be received within 48 hours of collection due to lability of RNA.

Stability:  Ambient: 4 hours; Refrigerated: 48 hours; Frozen: Unacceptable
Reference Interval:
By report
Interpretive Data: Refer to report.

Please refer to Statement B in the Compliance Statements section in the front of the Laboratory Test Directory.
Note: CBFB (core binding factor b-chain)-MYH11 (myosin heavy chain 11 gene) fusion transcripts are detected in approximately 10% of de novo acute myelogenous leukemias (AML).  One half of these cases belong to AML subtype M4 with abnormal eosinophils (AML-M4Eo).  The fusion results from a pericentric inversion on chromosome 16 inv(16)(p13q22) or rarely from the translocation t(16;16)(p13;q22).  Based on the breakpoints in the CBFB and MYH11 genes, greater than 95% of analyzed inv(16) cases belong to three types: A (88%), D (5%), and E (5%).
CPT Code(s): 83891 Isolation; 83902 Reverse transcription; 83913 RNA stabilization; 83898 x5 Amplification; 83894 x3 Gel separation; 83912 Interpretation and report - Additional CPT code modifiers may be required for procedures performed to test for oncologic or inherited disorders.
 
 

 

 

 
All ARUP Sites:        www.aruplab.com     ·     www.arupconsult.com     ·     www.arup.utah.edu     ·     www.childx.org     ·     www.utahblood.org